Crispr Therapeutics Stock Target Price and Analyst Consensus
| CRSP Stock | USD 35.76 0.38 1.05% |
The current analyst and expert consensus on Crispr Therapeutics is Buy with 10 hold recommendations. The current projected Crispr Therapeutics target price consensus is 81.46 with 28 analyst opinions. One of the most common ways Crispr Therapeutics analysts use to provide buy-or-sell recommendation to the public are conference calls analysis and financial statements evaluations. Some experts can also talk to Crispr Therapeutics vendors, executives, and/or customers. Crispr Therapeutics recommendation module provides expert sentiment on the projected Crispr Therapeutics target price to derive its highest and lowest estimates based on target price standard deviation of 4.5761.
Lowest Forecast 74.13 | Highest Forecast 90.42 | Target Price 81.46 |
It's important to approach Crispr Therapeutics' target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Crispr Therapeutics Target Price Consensus
Crispr target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Crispr Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 28 | Buy |
Most Crispr analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Crispr stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Crispr Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationCrispr Therapeutics Target Price Projection
Crispr Therapeutics' current and average target prices are 35.76 and 81.46, respectively. The current price of Crispr Therapeutics is the price at which Crispr Therapeutics AG is currently trading. On the other hand, Crispr Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Crispr Therapeutics Market Quote on 9th of May 2025
Target Price
Analyst Consensus On Crispr Therapeutics Target Price
Crispr Therapeutics Analyst Ratings
Crispr Therapeutics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Crispr Therapeutics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Crispr Therapeutics' financials, market performance, and future outlook by experienced professionals. Crispr Therapeutics' historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Crispr Therapeutics price targets
Crispr Therapeutics' stock target price is an estimate of its future price, usually made by analysts. Using Crispr Therapeutics' target price to determine if it is a suitable investment can be done through the following steps:- Look at Crispr Therapeutics' target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Crispr Therapeutics' stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Crispr Therapeutics Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Crispr Therapeutics is a key component of Crispr Therapeutics valuation and have some predictive power on the future returns of a Crispr Therapeutics.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Crispr Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Warren Buffett Holdings Invested few shares | |
 | Hedge Favorites Invested over 70 shares | |
 | Driverless Cars Invested over 60 shares | |
 | Momentum Invested few shares | |
 | Banking Invested over 40 shares | |
 | Power Assets Invested over 300 shares | |
 | Investor Favorites Invested few shares | |
Additional Tools for Crispr Stock Analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.